12M Interim Analysis of an Open-Label, Non-Randomized Extension of a Phase 2 Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Iptacopan in Subjects With C3G — Carla Nester (2022) | RDL Network
12M Interim Analysis of an Open-Label, Non-Randomized Extension of a Phase 2 Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Iptacopan in Subjects With C3G
Carla Nester, Ute Eisenberger, Alexandre Karras, Moglie Le Quintrec, Liz Lightstone, Manuel Praga, Giuseppe Remuzzi, María José Soler Romeo, Junhao Liu, Matthias Meier, Nicholas J.A. Webb, Edwin Wong
Carla Nester, Ute Eisenberger, Alexandre Karras, Moglie Le Quintrec, Liz Lightstone, Manuel Praga, Giuseppe Remuzzi, María José Soler, Junhao Liu, Matthias Meier, Nicholas J.A. Webb, Edwin KS Wong
C. Nester, Richard J.H. Smith, David Kavanagh, Marina Vivarelli, Giuseppe Remuzzi, Ming-hui Zhao, Edwin K.S. Wong, Y. Wang, Rubeen Israni, Hari Kalluri, Ipsita Krishnan, Jean Grisouard, Andrew S. Bomback
C. Nester, Ute Eisenberger, Alexandre Karras, Moglie Le Quintrec, Liz Lightstone, Manuel Praga, Giuseppe Remuzzi, María Soler, Junhao Liu, Rubeen Israni, Jean Grisouard, Ipsita Krishnan, Edwin Wong
Sebastian Grosicki, Markus Hansson, Meletios A Dimopoulos, Tadao Ishida, Vishal Kukreti, Dok Hyun Yoon, Wee Joo Chng, Oliver Bechter, Xuejun Peng, Paul Richardson
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.